Cel­gene antes up $195M more to stay close to For­ma, adding neu­rode­gen­er­a­tion fo­cus

What­ev­er Cel­gene $CELG learned dur­ing its lengthy col­lab­o­ra­tion with For­ma Ther­a­peu­tics must have been promis­ing. The big biotech is dou­bling down on For­ma, ex­tend­ing its pact and pick­ing up an op­tion to broad­en the scope of their re­search work, with For­ma adding new drugs fo­cused on pro­tein home­osta­sis, in­flam­ma­tion/im­munol­o­gy and neu­rode­gen­er­a­tion.

Cel­gene is pay­ing For­ma $195 mil­lion up­front for the ex­tend­ed re­la­tion­ship, hand­ing Cel­gene ex-US rights on drug can­di­dates through Oc­to­ber 1, 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.